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Abstract
Glioblastoma multiforme is an aggressive form of brain cancer
that originates from glial cells, which make up the supportive
tissue surrounding neurons. Temozolomide (TMZ) is the current
chemotherapeutic drug administered to treat glioblastoma as it
works to inhibit the growth of the cancer cells. This research
study focuses on developing a method for synthesizing novel
hybrid compounds that combines TMZ with various fatty acids
known to have anticancer properties, forming a series of imide
compounds with potential chemotherapeutic effects. Once the
novel hybrid compounds are successfully synthesized, they will be
tested for their anticancer properties on glioblastoma cells.

Methodology
A method for synthesizing an imide from a primary amide must
be developed first to ensure that the reaction combining TMZ
with a fatty acid will be successful. The current method being
tested uses 4-methoxybenzamide (primary amide) and valeryl
chloride (fatty acid chain). The method is essentially organized
into three steps:
1) Reaction
2) Isolation/Purification
3) Analysis/Identification
+

Introduction
Several studies have focused on developing more potent
chemotherapeutic drugs from novel hybrid compounds to treat
glioblastoma. The aim for this
project is to successfully synthesize
potential chemotherapeutic drugs
known as novel temozolomide-fatty
acid imide hybrid compounds.
Temozolomide (TMZ) is currently
being used in chemotherapy,
Figure 1. Structure of Temozolomide
along with radiation, to treat glioblastoma. However, glioblastoma
cells have developed a resistance to TMZ. Combining TMZ with
other compounds known to have anticancer properties is
hypothesized to overcome this resistance. An experiment done by
Maor et al. (2018) tested the effect of
physically combining TMZ with various
fatty acids, which have been studied
previously for anticancer activity.
Figure 2. General
Structure of Fatty Acids TMZ and fatty acids were found to have
antagonistic effects toward each other, inhibiting their respective
anticancer properties. Chemically combining the two compounds
may produce different results and have some cooperative
anticancer effect on glioblastoma cells. In addition to the
individual anticancer properties of TMZ and fatty acids, the
formation of the novel hybrid compound will produce an imide,
which is a functional group known to have a variety of biological
properties, including anticancer activity, and may also contribute
to the efficacy of the compounds.

Figure 3. Reaction between 4-methoxybenzamide (left) and valeryl chloride
(middle) to form a novel imide hybrid compound (right).

Once a method is developed, TMZ will be combined with various
fatty acid chains to produce a series of novel hybrid compounds
that can be tested on glioblastoma cells.

Results
A total of eight products have been synthesized so far.
Based on the NMR results in Figure 4, the desired product is
present, however it is not pure. It is possible that there may still
be some of the starting materials (4-methoxybenzamide and
valeryl chloride) that did not undergo the reaction.

Conclusion
Although there are no compounds that have been successfully
synthesized yet, we still have a contribution to the development of
a method for imide synthesis from a primary amide. There are
elements in the tested methods that have shown promise and
others that have not. Scientists can use the information in future
research to consider what may or may not work well in their own
experiments.
Future Work
• Optimize methodology for producing an imide from a primary
amide.
• Synthesize the novel Temozolomide-fatty acid imide hybrid
compounds.
• Test compounds on glioblastoma cells.
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Figure 4. NMR spectrum results for Product #7

